Glenmark Pharmaceuticals has entered into a development, license, manufacture, and commercial supply agreement with Cyndea Pharma S.L., granting exclusive rights to use their technology for developing generic, soft-gelatin capsule formulations of certain pharmaceutical products.

Under this agreement, Glenmark receives exclusive rights to the U.S. and Canadian markets for these soft-gelatin formulations in exchange for sharing development costs and profits from future sales. In addition, the agreement provides for the companies to add further soft-gelatin product candidates for development and commercialization, as new branded, soft-gelatin, capsule-based drug products become available in the marketplace.


A New Cancer Treatment

10 Unbelievable Innovation in Medicine

 

Digital version